Dr. Reddy's Laboratories (RDY) signed commercialization and license agreements with Bio-Thera Solutions for biosimilars BAT2206 and BAT2506 in Southeast Asia, Bio-Thera said Thursday.
Under the agreements, Bio-Thera will still oversee the development, manufacturing, and supply of the drugs, while Dr. Reddy's will manage the regulatory approval process and commercialization in licensed territories in Southeast Asia, including Cambodia, Indonesia, Malaysia, the Philippines, Thailand, and Vietnam.
Dr. Reddy's will also receive exclusive commercial rights to BAT 2206 in Colombia, according to Bio-Thera.
The company said BAT2206 is a proposed biosimilar to Jansen's Stelara, which has been approved in the EU for the treatment of a number of conditions, including moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis in adults.
BAT2506 is a proposed golimumab biosimilar to Simponi, which has been approved in the US for a number of conditions, including severe rheumatoid arthritis and active psoriatic arthritis, Bio-Thera said.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。